BioCorRx Pharmaceuticals Inc. has strategically positioned itself in the addiction treatment market through the acquisition of LUCEMYRA, a groundbreaking non-opioid medication designed to mitigate opioid withdrawal symptoms. The company's first-quarter financial results demonstrate the immediate impact of this strategic asset acquisition, with net product revenues surging from $3,620 in 2024 to $134,899 in 2025.
The acquisition of LUCEMYRA represents a critical advancement in addressing the complex challenges of opioid use disorder (OUD), a chronic condition characterized by significant health risks, including potential disability, relapse, and mortality. As the first and only FDA-approved non-opioid medication specifically targeting opioid withdrawal symptoms, LUCEMYRA offers a pivotal treatment option for individuals navigating the challenging process of opioid detoxification.
Concurrent with the LUCEMYRA acquisition, BioCorRx continues to develop innovative treatment solutions, including BICX104, a subcutaneous naltrexone implantable pellet targeting methamphetamine use disorder (MUD). Supported by a substantial grant from the National Institutes of Health's National Institute on Drug Abuse, this research addresses a critical gap in treatment options for a condition affecting millions nationwide.
The company's strategic approach extends beyond pharmaceutical development, incorporating comprehensive treatment programs like Beat Addiction Recovery, which combines proprietary cognitive behavioral therapy modules with medication-assisted interventions. This holistic methodology reflects a nuanced understanding of substance use disorders as complex, multifaceted health challenges requiring integrated treatment strategies.
By reducing operating expenses by approximately 9% compared to the same period in 2024, BioCorRx demonstrates fiscal discipline while simultaneously expanding its therapeutic portfolio. CEO Lourdes Felix emphasized the company's commitment to driving revenue growth and enhancing shareholder value through strategic acquisitions and focused research initiatives.
The acquisition of LUCEMYRA and ongoing development of BICX104 position BioCorRx at the forefront of innovative addiction treatment solutions, addressing critical public health challenges with scientifically rigorous and patient-centered approaches.
